Abstract
The effects of nasal airway resistance of the β-adrenoceptor stimulants terbutaline (Bricanyl®) and KWD 2131 intranasally have been studied by means of posterior rhinomanometry in 16 healthy volunteers and 13 asymptomatic patients with allergic rhinitis. The study was performed as a randomized, placebo-controlled, double-blind crossover trial. No obvious changes in nasal resistance were revealed. This makes the nasal mucosa a suitable organ for testing the capacity of β-adrenoceptor stimulants to reduce the release of mediators from mast cells after allergen challenges.